Belzutifan Alleviates Knee Osteoarthritis by Inhibiting Chondrocyte Ferroptosis via the HIF-2α/ACSL4 Axis
Background: Knee osteoarthritis (KOA) is a debilitating degenerative joint disease that significantly reduces quality of life, with no definitive treatments currently available. Recent research has highlighted the pathogenic role of hypoxia-inducible factor-2α (HIF-2α) in KOA. Belzutifan, originally developed as an anti-cancer drug, has demonstrated substantial therapeutic promise as a HIF-2α inhibitor for KOA treatment. Objective: This study aimed to investigate the underlying mechanism by which belzutifan alleviates KOA through both in vivo and in vitro experiments. Methods: Initially, Safranin O-fast green staining and immunohistochemistry (IHC) were conducted to assess the chondroprotective effects of belzutifan in a rat KOA model. Bioinformatic analyses and molecular docking simulations were then performed to predict the potential involvement of HIF-2α in chondrocyte injury associated with KOA. Finally, primary rat chondrocytes were isolated and cultured to validate the downstream signaling pathway targeted by belzutifan treatment in vitro. Results: In vivo, belzutifan significantly inhibited the expression levels of matrix metalloproteinase-13 (MMP-13) and HIF-2α in articular cartilage of KOA model rats, enhanced collagen type II alpha 1 chain (COL2A1) expression, and demonstrated a protective effect on articular cartilage. Bioinformatic analysis of the GSE104794 microarray dataset indicated that HIF-2α overexpression in chondrocytes activates ferroptosis signaling, notably upregulating the ferroptosis master regulator acyl-CoA synthetase long-chain family member 4 (ACSL4). Thus, we hypothesized that belzutifan exerts its therapeutic effect on KOA by inhibiting chondrocyte ferroptosis via the HIF-2α/ACSL4 axis. This hypothesis was confirmed through in vitro experiments, showing that belzutifan effectively reduced IL-1β-induced reactive oxygen species (ROS) and malondialdehyde (MDA) levels in chondrocytes, suppressed the expression of pro-inflammatory cytokines, and enhanced mitochondrial membrane potential. Furthermore, belzutifan significantly downregulated MMP-13 and ACSL4 expression while upregulating COL2A1 and glutathione peroxidase 4 (GPX4) expression. ACSL4 overexpression reversed these beneficial effects, confirming the involvement of the HIF-2α/ACSL4/ferroptosis pathway in belzutifan action. Conclusion: Belzutifan attenuates cartilage damage and slows KOA progression by suppressing chondrocyte ferroptosis mediated by the HIF-2α/ACSL4 axis. These results underscore belzutifan as a promising therapeutic candidate for KOA.
Authors
- Zhe Song (ORCID: https://orcid.org/0000-0001-9156-0094)
- Weijia Zhang (ORCID: https://orcid.org/0000-0002-6427-0056)
- Qing Xie (ORCID: https://orcid.org/0009-0008-3597-5621)
- Long-Xiao Gao
- Dong Shen
- Jia-Jian Guo
Institutions
- Shandong University (CN)
- Second Hospital of Shandong University (CN)
- Affiliated Hospital of Shandong University of Traditional Chinese Medicine (CN)
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- Journal of Food and Drug Analysis
- Published
- 2026-11-16
- DOI
- https://doi.org/10.38212/2224-6614.3615
- Primary Topic
- Osteoarthritis Treatment and Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00